DARE

0.43513.74%
SL

Susan L. Kelley

Independent Director

Dr. Susan L. Kelley, M.D., is Director at A2 Biotherapeutics, Inc. since January 2022. Dr. Kelley was an Independent Director at Deciphera Pharmaceuticals, Inc. since July 08, 2019 until June 11, 2024. Dr. Kelley served as a Non-Executive Director of Vascular Biogenics Ltd. since January 3, 2018 until October 30, 2020 and also served as Head of Scientific Advisory Board since February 2020. Dr. Kelley had been an Independent Director at IDEAYA Biosciences, Inc. since February 12, 2021 until 2025. Dr. Kelley served as the Chief Medical Officer of Multiple Myeloma Research Consortium and The Multiple Myeloma Research Foundation/Consortium from July 2008 to March 2011, where her leadership responsibilities included the strategic design and management of clinical trials conducted by leading myeloma clinical research centers in North America. Dr. Kelley is a successful is an oncologist with extensive experience in drug research, commercialization and development to IDEAYA. Dr. Kelley has been developing drugs in oncology and immunology for many years. Dr. Kelley spanned the continuum of clinical drug development from translational research and clinical trials to FDA regulatory compliance. From 2001 to 2008, she served at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma in Germany and served as its Vice President of Global Strategic Drug Development - Cancer and Metabolics from April 2001 to May 2002 and Vice President of Global Clinical Development and Therapeutic Area Head-Oncology from May 2002 to June 2008, where she led the Bayer team and was responsible for the development and worldwide regulatory approval of Nexavar(R) (sorafenib), including a renal cell carcinoma indication. She led the Bayer team responsible for the development and worldwide regulatory approval of Nexavar (sorafenib) in kidney cancer and liver cancer and was also responsible for clinical development of the early pipeline drug candidates. She worked in Oncology and Immunology drug development at Bristol-Myers Squibb Company from 1987 to 2001 as an Executive Director of Oncology Clinical Research at the Bristol-Myers Squibb Pharmaceutical Research Institute. She was an Independent Consultant to the pharmaceutical and biotechnology industries in the field of oncology drug development and strategy. She served as a Clinical Assistant Professor of Medicine at Yale University School of Medicine. She served as Director at VBL Therapeutics Ltd. She had been a Director at Immune Design Corp. since June 16, 2016 until April 02, 2019. She has been a Director at Daré Bioscience, Inc. since October 2014. She has been a Director of Audeo Oncology, Inc. since September 28, 2012. She had been an Independent Director of ArQule, Inc. since April 27, 2011 until January 16, 2020. She served as a Director of Cerulean Pharma Inc. from October 2014 to 2017. She served as a Director of Alchemia Pty Ltd from 2013 to 2015. She served as a Non-Executive Director of Alchemia Limited in Australia from March 22, 2013 to June 10, 2015. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine. Dr. Kelley also serves as an Entrepreneur-in-Residence at the Yale University Office of Cooperative Research. She has an A.B. in Biology, magna cum laude from Colgate University and an M.D. from Duke University School of Medicine.

Positions